about
Staphylococcal Superantigens Spark Host-Mediated Danger SignalsPI3K/Akt/mTOR, a pathway less recognized for staphylococcal superantigen-induced toxicityPost orgasmic illness syndrome (POIS)Optimized expression and specific activity of IL-12 by directed molecular evolution.Bell's palsy during interferon therapy for chronic hepatitis C infection in patients with haemorrhagic disorders.Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele.Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitorRecombinant proteins for genetic disease.Responses of the immune system to injury.Postorgasmic illness syndrome: two cases.Hypothyroidism in Noninterferon Treated-HCV Infected Individuals Is Associated with Abnormalities in the Regulation of Th17 Cells.Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis.Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis.Construction of Recombinant Single Chain Variable Fragment (ScFv) Antibody Against Superantigen for Immunodetection Using Antibody Phage Display Technology.Analysis of in vitro secretion profiles from adipose-derived cell populations.Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo.Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions.Opportunistic autoimmune disorders: from immunotherapy to immune dysregulationThe Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop.Management of metastatic renal cell carcinoma: current trends.Residual DNA analysis in biologics development: review of measurement and quantitation technologies and future directions.Therapeutic down-modulators of staphylococcal superantigen-induced inflammation and toxic shock.Hughes syndrome and multiple sclerosis.Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders.Toxic response of graphene nanoplatelets in vivo and in vitro.Polyarteritis nodosa. Diagnostic challenges in a patient with cutaneous vasculitis, psoriasis, psoriatic arthritis and pancytopenia: fatal progression after treatment with G-CSFIL4 gene polymorphisms in Iranian patients with autoimmune hepatitis.Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog.Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.Bistability in autoimmune diseases.Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemiaEmerging classes of armed antibody therapeutics against cancer
P2860
Q26766421-303C1B63-E628-414F-83E6-01047CFFCBEFQ26825729-82C223AC-2715-4DB8-BB3E-8EC2D52B7992Q28066724-4685DA63-5D69-43BA-ACD3-CD91D1772FA9Q33185720-08667D43-CEFB-4C7F-86D1-9A472D0C89EAQ33332223-2F3E0F52-BAF0-4769-9B75-4AE6FD6CD4FBQ33544158-9ABB462A-78A0-4D5D-BCB9-B7E71E300F1FQ33713477-675FC2E4-6EDC-4688-8B17-18852D62760EQ33713530-4F10A9E8-6663-4E6F-B97B-D1C6D25FEB52Q33947678-D90C3448-E9D8-4DF9-B559-BE9F7A8D0873Q33958966-EE441C2E-4C24-47A6-B503-27A97F2FCC2BQ34415214-ED2EF772-FEB2-47DB-9219-5B675E7BF52DQ35137333-42E8D5DA-FC86-4245-9E2D-AC71BF4EED09Q35636977-1009C08A-7E99-486E-8D9C-D52AA779E12FQ35871037-91C39AD3-4A66-43CD-A58E-240E4EB81130Q36341286-77AE4001-6EA1-4C39-8602-169AA1C21490Q36380807-3405D1A1-EE3A-473A-8C93-D155F5EE3A27Q37235247-16449F88-A9AA-4640-9629-D64BBFA4B6F6Q37274049-A7F68089-E83D-4B54-A41A-2FC917A98C8FQ37311022-511213B0-8ED6-45B8-AC62-E05052CD5093Q37355884-3222B707-E9BB-4D8F-92AD-E165829208B6Q37940194-55EAF908-CCC2-4B7D-9F79-E58462C550CCQ37954312-DE0F7861-3402-40DD-A0DF-1433ABD5E4FCQ38261156-921770CC-EBD9-4BEE-9B38-7F64EFC71674Q38267711-661882BF-8FF2-4EBC-8CF6-AF3C7458F42BQ38979554-2D9301C5-A264-4A5C-9FA7-B3F3E1558F8BQ40627700-17DB8F7C-685E-4260-B3EC-F996FA517643Q40843798-76C0F835-1A76-4A7F-AF1B-8FD99F63FD90Q40897178-2FB2350E-696D-468A-BF75-0BA51EBA2A00Q47287952-8F2E80C1-923C-4CDD-BE73-80BE2DB1F552Q51612141-E08441D5-0248-4608-A24B-C7B5327D3B84Q56985898-C2D9C923-E179-4838-A592-DC80F9CFDA0FQ57911948-45C0A1C9-75DE-4FAD-AC50-D3C956B316CF
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Immune-mediated side-effects of cytokines in humans.
@ast
Immune-mediated side-effects of cytokines in humans.
@en
Immune-mediated side-effects of cytokines in humans.
@nl
type
label
Immune-mediated side-effects of cytokines in humans.
@ast
Immune-mediated side-effects of cytokines in humans.
@en
Immune-mediated side-effects of cytokines in humans.
@nl
prefLabel
Immune-mediated side-effects of cytokines in humans.
@ast
Immune-mediated side-effects of cytokines in humans.
@en
Immune-mediated side-effects of cytokines in humans.
@nl
P1433
P1476
Immune-mediated side-effects of cytokines in humans.
@en
P2093
P356
10.1016/0300-483X(95)03124-X
P407
P577
1995-12-01T00:00:00Z